查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1644900

菲律宾医药包装：市场占有率分析、行业趋势和成长预测（2025-2030 年）

Philippines Pharmaceutical Packaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
出版日期: | 出版商: Mordor Intelligence | 英文 83 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

菲律宾医药包装市场规模预计在 2025 年为 1.7652 亿美元，预计到 2030 年将达到 2.1976 亿美元，预测期内（2025-2030 年）的复合年增长率为 4.48%。

COVID-19疫情对菲律宾医药包装产业既有正面影响，也有负面影响，为产业组织创造了许多潜在的机会和挑战。与许多其他行业一样，由于旅行限制、封锁措施和劳动力短缺，COVID-19 疫情始于医药包装行业受到严重干扰。

关键亮点

  • 根据世界银行的资料，2021年菲律宾人口将超过1.11亿人。菲律宾目前是世界第十三大人口大国，也是东协第二大人口大国。此外，根据世界银行的资料，2021年菲律宾人口中5.7%将年龄在65岁或以上，成长率高于整体人口。这个年龄层的人更容易罹患心血管疾病、高血压、糖尿病、呼吸系统疾病等併发症。人口的成长和新兴经济体的快速发展为中国医药产业提供了光明的市场前景。
  • 新冠疫情凸显了该国製药业的重要性。Astra Zeneca等跨国公司的存在帮助该国快速获得更多疫苗。当地生产对抗新冠肺炎的药物对于挽救生命和减少住院至关重要。预计这些发展将增加医药包装市场的投资潜力。
  • 此次疫情凸显了国内製药业发展的必要性。因此，菲律宾投资委员会（BOI）正在积极推动菲律宾成为製药公司生产 COVID-19 药物和疫苗的製造地。例如，2022 年 1 月，投资委员会 (BOI)核准了Lloyd Laboratories, Inc. 的一项 2,400 万菲律宾计划，用于在当地生产 COVID-19 药物莫努匹韦。预计 COVID-19 疫情的影响将导致医疗保健支出增加。由于 COVID-19 病毒爆发，製药公司也发现维持药物和综合维他命的需求激增。
  • 全民健康覆盖（UHC）等政府计划的实施、对优质学名药的需求不断增长、大量弱势群体、人均医疗支出的增加以及跨国公司的投资增加是成长要素。
  • 根据菲律宾製药商协会（PPMA）统计，在实施全民健康覆盖（UHC）之前，只有近三分之一的菲律宾人口能够获得足够的药品。随着全民健保（UHC）计画的实施，政府旨在为民众，特别是贫困阶级人口提供必要的医疗服务和解决方案。因此，未来几年药品供应将有很大机会，而且对更便宜的学名药的需求预计会增加，以确保大众能够获得医疗保健。

菲律宾医药包装市场趋势

药品需求激增和针对仿冒品的严格规范预计将推动市场成长

  • 在菲律宾，有组织的药局零售连锁店正在迅速发展。为了更快发展，连锁药局正在收购独立药局和当地连锁药局。马尼拉、中吕宋和比科尔地区是新店分店的主要目标区。随着市场集中度日益提高，各家公司都专注于在不同的省份和欠发达地区分店，尤其是在维萨亚斯群岛。
  • 在菲律宾，药品分为三个部分：原始药品、品牌非专利和非品牌非专利。由于製造成本低和多年的高销量，许多製药公司选择生产更多的品牌药和学名药。
  • 据卫生署称，菲律宾全国正在经历多起疾病爆发。 2019年和2020年，菲律宾因急性上呼吸道感染死亡的人数将达到数百万。影响社区的其他主要疾病是高血压、尿道感染、急性下呼吸道感染疾病和肺炎、皮肤病、动物咬伤、支气管炎和流感。这导致对医药产品的需求激增，从而带动包装市场的成长。
  • 疾病正在从感染疾病疾病转向非感染疾病，由于饮食、饮酒和缺乏运动等原因，心臟病等疾病正在迅速增长。菲律宾对医疗产品和药品有需求。根据菲律宾统计局 (PSA) 的数据，2019 年至 2020 年间，该国经常性医疗支出 (CHE) 增加了 10.9%，总额约为 7,920 亿菲律宾比索（165 亿美元）。
  • 由于政府采取了一系列改革措施以及推出「全民健康纳保」（UHC）计划，这一步伐正在加快，该计划为所有菲律宾人提供了基本水平的医疗保健。还有一项新法律要求公立医院提供学名药，以便为菲律宾人提供负担得起的医疗服务。目前，全球20大製药公司中有14家在菲律宾设有製造地。随着政府简化商业报名手续，製药业的商机每年都在扩大和成长。
  • 根据菲律宾卫生署（DOH）和食品药物管理局的数据，2021年，菲律宾共有约31,650家持牌药品机构，其中约22,000家为药局。菲律宾领先的药局是 Generics Pharmacy 和 Mercury Drug。同时，全国有6,000多家药品分销商。

公民健康问题的加剧将推动市场成长

  • 在菲律宾，78%的人口都有保险，品牌药物占据市场主导地位。对製药公司来说，菲律宾是全球第11大最具吸引力的市场，也是东南亚国协中第三大最具吸引力的市场。这主要是由于多种因素造成的，包括人口增长、医疗旅游率高以及其他类似因素。
  • 菲律宾人收入的快速成长和严重依赖进口的医疗保健产业创造了外国公司可以利用的国内需求。根据业内专家调查显示，心臟衰竭、心臟病等心血管疾病和癌症是菲律宾两大死因。为了确保热敏性抗癌药物的功效，选择绝缘包装解决方案作为二次包装和选择容器作为一次包装至关重要。
  • 在菲律宾，就像在其它中低收入国家一样，糖尿病正迅速成为一个主要的公共卫生问题。治疗和药物的可近性和可负担性是控製糖尿病的关键。在菲律宾，每 14 个菲律宾成年人中就有 1 个患有糖尿病。截至2019年，根据国际糖尿病联盟（IDF）的资料，菲律宾当时的成年人口为63,265,700，其中3,993,300人患有糖尿病，成人糖尿病盛行率为6.3%。预计未来全国糖尿病患者数量将持续增加，将满足大量胰岛素的需求，从而带动容器及包装的需求量庞大。
  • 此外，菲律宾公共服务署的数据显示，过去五年来，家庭医疗支出逐渐增加，并在 2021 年新冠疫情爆发后达到最高。 2021年，菲律宾家庭最终消费支出约菲律宾披索。
  • 菲律宾政府和卫生部门面临着改变医疗保健方式的巨大压力。需求的主要驱动力是人口成长和老化。根据联合国统计，2015年，65岁及以上人口占总人口的比例达到约4.6%。预计到2100年，65岁以上人口将达到25.6%。预计到2100年，65岁以上人口将达到25.6%。这项因素满足了瓶子和容器、注射器和药筒、管瓶和安瓿瓶、小袋和包装等主要的包装需求，预计将导致该国对学名药的需求大幅增加。预计葡萄糖输注将满足因人口老化而产生的巨大需求。这可能会导致对袋装包装的需求，而袋装包装是包装葡萄糖所必需的。
  • 根据Trend Economy报道，2020年印度约占菲律宾药品进口量的15.7%，其次是德国（13.4%）和美国（11.5%）。新加坡（21%）、泰国（14.8%）和日本（12.5%）占菲律宾出口的很大份额。预计未来这些国家的进出口趋势仍将持续。这可能会导致对药品包装的巨大需求。此外，菲律宾製药工业协会（PPMA）表示，全民健康保险制度的实施将支持未来五年的产业成长。政府的全民健康保险计划为本地製造商和外国供应商提供了透过政府竞标参与药品供应的机会。

菲律宾医药包装产业概况

菲律宾的医药包装市场竞争激烈，有 Robicel Trading、Euro-med Laboratories Phil.Inc.、Bestpak packaging Solutions Inc. 和 Netpak Phils.Inc. 等公司。这些占据大量市场份额的大公司正专注于扩大海外基本客群。这些公司正在利用策略合作计划来扩大市场占有率并提高盈利。

  • 2022 年 5 月-中国製药公司依生生物药业表示，计划与当地企业寻求投资收益，共同开发、製造和销售临床试验和疫苗。依生生物药业已经与当地製药公司签署了协议，据说正在与其他当地企业会面，讨论可能的合作伙伴关係，以实现疫苗的商业化。

其他福利

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

目录

第 1 章 简介

  • 研究假设和市场定义
  • 研究范围

第二章调查方法

第三章执行摘要

第四章 市场洞察

  • 医药市场概览
  • 关键市场影响者
  • COVID-19 对市场的影响
  • 主要製药公司名单
  • 药品包装 - 市场概览

第五章 市场动态

  • 市场驱动因素
    • 药品需求激增，打击仿冒品的规定愈发严格
  • 市场问题
    • 由于包装基地有限，依赖其他国家
  • 市场趋势
  • GMP 法规

第六章 竞争格局

  • 公司简介
    • Robicel Trading
    • Euro-med Laboratories Phil., Inc.
    • Bestpak Packaging Solutions, Inc.
    • Netpak Phils., Inc.
    • GL Otometz Corporation
    • Plastic Container Packaging Corporation（PCPC）
    • APO International Marketing Corporation
    • Merfel Plastic Products
    • Versa Group Philippines Corporation
    • SwissPac
    • Berry Global Inc.
    • Shandong Pharmaceutical Glass Co., Ltd
    • Amcor Flexibles Philippines Corp.（Amcor PLC）

第七章 市场展望

简介目录
Product Code: 91873

The Philippines Pharmaceutical Packaging Market size is estimated at USD 176.52 million in 2025, and is expected to reach USD 219.76 million by 2030, at a CAGR of 4.48% during the forecast period (2025-2030).

The COVID-19 pandemic had both positive and negative impacts on the pharmaceutical packaging industry of the Philippines, therefore creating many potential opportunities and challenges for organizations in the industry. Like many other sectors, the COVID-19 pandemic started with significant disruptions in the pharmaceutical packaging sector owing to travel restrictions, lockdown measures, and labor shortages.

Key Highlights

  • The World Bank data indicates that the Philippines population will reach the 111-million mark in 2021. The country is currently the 13thmost populous country in the world and the 2ndmost populated among the ASEAN member states. Further, the World Bank Data indicated that, in 2021, 5.7% of the Philippine population was aged 65 years and above and increasing at a higher rate than the overall population. This age group, medically, is prone to have comorbidities such as cardiovascular diseases, hypertension, diabetes, and respiratory diseases. Such a growing population, along with a rapidly developing economy, provides a bright market outlook for the country's pharmaceutical sector.
  • The COVID-19 pandemic highlighted the importance of the pharmaceutical industry in the country. The presence of multinational companies such as AstraZeneca helped the country to secure more vaccines at a rapid pace. The local production of medicines against COVID-19 was crucial to saving lives and reducing hospitalization in the country. Such developments are expected to create increased potential for investment in the pharmaceutical packaging market.
  • The pandemic highlighted the need for a robust domestic pharmaceutical industry. Hence, the Board of Investments (BOI) of the Philippines has been actively promoting the country as a manufacturing hub for pharmaceutical companies to manufacture COVID-19 medicines and vaccines. For instance, in January 2022, the Board of Investments (BOI) approved a PHP 24 million project of Lloyd Laboratories, Inc. to manufacture the COVID-19 drug Molnupiravir in the country. The impact of the COVID-19 pandemic is expected to increase the spending on healthcare. Pharmaceutical companies have also witnessed a surge in demand for maintenance medicines and multivitamins owing to the COVID-19 virus outbreak.
  • Implementation of government schemes such as Universal Health Coverage (UHC), rising demand for high-quality generics, high volume of a vulnerable population, growing per capita health expenditure, and increasing investments from multinational market players are some of the growth drivers of the pharmaceutical industry in the country.
  • According to the Philippine Pharmaceutical Manufacturers Association (PPMA), before the implementation of the Universal Health Care (UHC) program, only nearly one-third of the Philippine population had access to the right medicine. With the implementation of the Universal Health Care (UHC) program, the government is intended to supply the required health care services and solutions, particularly to the poor member of society. Therefore, there is an opportunity during the next few years to provide a large volume of medicine in the country, with generic medicine demand expected to increase, owing to its lesser pricing, to make healthcare accessible to the masses.

Philippines Pharmaceutical Packaging Market Trends

Surge in Demand for Medicines and Stringent Norms Against Counterfeit Products are Expected to Drive the Market Growth

  • Organized pharmacy retail chains are growing aggressively in the Philippines. In order to achieve speedy growth, the pharmacy chains are acquiring independent pharmacies and regional chains as it helps them to save the costs and operations to open a pharmacy store and build it up from scratch. Manila, Central Luzon, and Bicol Region have been key target regions for opening new pharmacies. As the market is becoming concentrated day by day, the companies are focusing on opening stores in different provinces and less developed regions of the country, especially in the Visayas Islands.
  • In the Philippines, pharmaceutical drugs are regulated into three segments, namely, originator, branded generics, and unbranded generics. Due to its low manufacturing costs and high sales over the years, many pharmaceutical corporations opted for producing more branded and unbranded generics.
  • According to DOH (Philippines), in the Philippines, several diseases are prevalent throughout the country. The number of deaths due to acute upper respiratory disease among Filipinos amounted to millions in 2019 and 2020. The other leading diseases affecting communities are hypertension, urinary tract infection, acute lower respiratory tract infection and pneumonia, skin disease, animal bites, bronchitis, and influenza. This is leading to a major surge in demand for drugs, leading to growth in the packaging market.
  • The shift has been made from infectious disease to non-communicable disease, with diet, alcohol, and low exercise causing heart disease and other conditions to grow rapidly. Healthcare products and medicines are in demand in the Philippines. According to the Philippine Statistics Authority (PSA), the country's current health expenditure (CHE) has grown by 10.9% in 2019-2020, reaching a total amount of approximately PHP 792 billion (USD 16.5 billion).
  • There is a high acceleration rate due to numerous government reforms and the introduction of a Universal Health Coverage (UHC) scheme, which provides the basic level of healthcare to all Filipinos. There are also new laws mandating public hospitals to provide generic drugs so as to give affordable medicine to Filipinos. At present, 14 of the world's top 20 pharmaceutical companies own a manufacturing base in the Philippines. With government efforts to ease the business registration process in the country, business opportunities in the industry have grown and expanded over the years.
  • As per DOH (Philippines) and Food & Drug Administration, In 2021, there were around 31.65 thousand licensed drug establishments in the Philippines, nearly 22 thousand of which were drugstores. Among the leading drugstores in the country were The Generics Pharmacy and Mercury Drug. On the other hand, there were over six thousand drug distributors in the country.

Increasing Health Issues Among the Citizens is Expected to Drive the Market Growth

  • In the Philippines, 78% of the population has insurance coverage, and branded drugs dominate the market. The Philippines was the 11th most attractive market globally for pharmaceutical companies and the 3rd most attractive among the ASEAN countries. This is majorly due to various factors such as the growing population, high rate of medical tourism, and other similar factors (source: Pharmaceutical & Healthcare Association of the Philippines (PHAP)).
  • The rapid increase in income among Filipinos and the medical industry's heavy reliance on imports create a demand within the country that foreign firms can take advantage of. The industry expert studies show that cardiovascular diseases, such as heart failure, heart attacks, and cancer, are the two leading causes of death in the Philippines. To ensure the efficacy of anticancer drugs, which are heat-sensitive, it is essential to opt for insulated packaging solutions as secondary packaging and container as primary packaging.
  • In the Philippines, diabetes is rapidly becoming a major public health issue, as in other low- and middle-income countries. Availability and affordability of care and medicines are crucial to controlling diabetes. In the Philippines, 1 in 14 Filipino adults lives with diabetes. As of 2019, International Diabetes Federation (IDF) data showed that 3,993,300 of the then total 63,265,700 Filipino adult population had diabetes, with a 6.3% prevalence of diabetes in adults. In the coming time, it is expected that the number of diabetic patients will increase in the country, which is expected to cater to a major demand for insulin, leading to major demand for container packaging.
  • Moreover, according to PSA (Philippines), household spending on health has gradually increased over the past five years and was highest in 2021 after the COVID-19 pandemic outbreak. In 2021, the household final consumption expenditure for health in the Philippines was valued at approximately 627 billion Philippine pesos.
  • There is significant pressure on the government and the healthcare sector to revolutionize the state of Philippine healthcare. Demand is primarily driven by a growing and aging population. According to United Nations, in 2015, the share of the population older than 65 amounted to about 4.6 percent. In 2100, the population above 65 was forecasted to reach 25.6 percent. The share of the aging population was forecasted to increase throughout the years. This factor would lead to major generic medicine demand in the country, catering to the major packaging needs such as bottles & containers, syringes & cartridges, vials & ampoules, and pouches & packs. Glucose drip is expected to cater to a major demand due to the aging population. This would lead to demand for pouch packaging, which is needed for glucose packaging.
  • According to Trend Economy, India had a major import share of pharmaceutical products in the Philippines, with around 15.7% in 2020, Germany with 13.4%, and the United States with 11.5%. In the context of export to the Philippines, the major share was of Singapore (21%), Thailand (14.8%), and Japan (12.5%). It is expected that the same trend for import-export for these countries will continue in the future. This would lead to major demand for pharma packaging. Further, according to Philippine Pharmaceutical Manufacturers Association (PPMA), the industry's growth in the next five years will be supported by the implementation of the universal health care program. The Universal Health Care program by the government will give local manufacturers and foreign traders opportunities to participate in the supply of pharmaceutical products through government bids.

Philippines Pharmaceutical Packaging Industry Overview

The Philippines Pharmaceutical Packaging Market is highly competitive and is dominated by several major players like Robicel Trading, Euro-med Laboratories Phil. Inc., Bestpak packaging Solutions Inc., Netpak Phils. Inc, among others. These major players with a prominent share in the market are focusing on expanding their customer base across foreign countries. These companies leverage strategic collaborative initiatives to increase their market share and increase their profitability.

  • May 2022 - Yisheng Biopharma Co., Ltd., a China-based pharmaceutical company, discussed its plans to pursue investment interests in clinical trials and for the co-development or manufacturing and marketing of vaccines with a local company. Yisheng Biopharma already has an engagement with a local pharmaceutical company, and the company is said to meet with other local firms for potential partnerships on the commercialization of its vaccines.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS

  • 4.1 Pharmaceutical Sector - Market Overview
  • 4.2 Key Market Influencers
  • 4.3 Impact of COVID-19 on the Market
  • 4.4 List of Major Pharmaceutical Companies
  • 4.5 Pharmaceutical Packaging - Market Overview

5 MARKET DYNAMICS

  • 5.1 Market Drivers
    • 5.1.1 Surge In Demand For Medicines And Stringent Norms Against Counterfeit Products
  • 5.2 Market Challenges
    • 5.2.1 Dependent On Other Countries Due To Low Packaging Hubs
  • 5.3 Market Trends
  • 5.4 GMP Regulations

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Robicel Trading
    • 6.1.2 Euro-med Laboratories Phil., Inc.
    • 6.1.3 Bestpak Packaging Solutions, Inc.
    • 6.1.4 Netpak Phils., Inc.
    • 6.1.5 GL Otometz Corporation
    • 6.1.6 Plastic Container Packaging Corporation (PCPC)
    • 6.1.7 APO International Marketing Corporation
    • 6.1.8 Merfel Plastic Products
    • 6.1.9 Versa Group Philippines Corporation
    • 6.1.10 SwissPac
    • 6.1.11 Berry Global Inc.
    • 6.1.12 Shandong Pharmaceutical Glass Co., Ltd
    • 6.1.13 Amcor Flexibles Philippines Corp. (Amcor PLC)

7 MARKET OUTLOOK